<DOC>
<DOCNO>EP-0625138</DOCNO> 
<TEXT>
<INVENTION-TITLE>
NOVEL AMIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS WITH LTB4 ANTAGONISTIC EFFECT
</INVENTION-TITLE>
<CLASSIFICATIONS>A61K31352	A61P1100	C07D31918	C07C30340	A61K31357	A61K3142	A61K3134	A61K31415	C07C32300	C07D27700	C07C25700	A61P2900	C07C31504	C07C32320	C07C32362	A61K31155	C07D21300	C07C31718	A61K3135	C07C31500	A61K31155	C07D30779	C07D31900	A61K31357	A61P1100	C07C31722	C07D31700	A61P1700	C07C32332	C07D31100	C07D33300	C07D30700	C07C30300	A61K31421	A61P104	A61P3708	A61K3134	C07C31700	C07C31744	A61K31352	A61K3140	C07D23100	C07D23100	C07D26332	C07C31920	A61K3135	C07C31129	A61K3142	C07D21378	C07C31100	A61P3700	A61P100	A61P1106	C07C32318	A61K31421	C07D27700	A61K31343	A61K31343	A61P1706	A61K3140	C07C31900	C07D31766	C07D31122	C07C25718	A61K31415	C07D26300	A61P2900	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61K	A61P	C07D	C07C	A61K	A61K	A61K	A61K	C07C	C07D	C07C	A61P	C07C	C07C	C07C	A61K	C07D	C07C	A61K	C07C	A61K	C07D	C07D	A61K	A61P	C07C	C07D	A61P	C07C	C07D	C07D	C07D	C07C	A61K	A61P	A61P	A61K	C07C	C07C	A61K	A61K	C07D	C07D	C07D	C07C	A61K	C07C	A61K	C07D	C07C	A61P	A61P	A61P	C07C	A61K	C07D	A61K	A61K	A61P	A61K	C07C	C07D	C07D	C07C	A61K	C07D	A61P	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61K31	A61P11	C07D319	C07C303	A61K31	A61K31	A61K31	A61K31	C07C323	C07D277	C07C257	A61P29	C07C315	C07C323	C07C323	A61K31	C07D213	C07C317	A61K31	C07C315	A61K31	C07D307	C07D319	A61K31	A61P11	C07C317	C07D317	A61P17	C07C323	C07D311	C07D333	C07D307	C07C303	A61K31	A61P1	A61P37	A61K31	C07C317	C07C317	A61K31	A61K31	C07D231	C07D231	C07D263	C07C319	A61K31	C07C311	A61K31	C07D213	C07C311	A61P37	A61P1	A61P11	C07C323	A61K31	C07D277	A61K31	A61K31	A61P17	A61K31	C07C319	C07D317	C07D311	C07C257	A61K31	C07D263	A61P29	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Compounds of formula (I), which are defined in more detail in the description, can be prepared by conventional methods and are used for therapeutic purposes in the usual galenical preparations.
</ABSTRACT>
<APPLICANTS>
</APPLICANTS>
<INVENTORS>
</INVENTORS>
<CLAIMS>
Compounds of the formula


wherein

R
1
 and R
2
,
which may be identical or different, denote
CF
3
, halogen, R
5
, OR
5
, COR
6
, SR
6
, SOR
6
, SO
2
R
6
, SO
2
NR
5
R
7
,
C(OH)R
5
R
7
 or together may also denote the double-bonded
groups -CH=CH-CH=CH-, -CR
8
=CH-CH=CH-,
-CH=CR
8
-CH=CH-, -O-CH
2
-CH
2
-, -O-CH
2
-O-, -O-CH
2
-CH
2
-O-,
-(CH
2
)
3-4
-, -NH-CO-O-, -NH-CO-CH
2
-O-, -CO-CH
2
-O- or
-CO-CH
2
CH
2
-O-, linked with adjacent carbon atoms of
the benzene ring, whilst these groups may in turn

be substituted by C
1-4
-alkyl,
R
3
denotes halogen, OH, CF
3
, R
5
, OR
6
, COR
6
, SR
6
, SOR
6
,
SO
2
R
6
, SO
2
NR
5
R
7
, NR
5
R
7
 or C(OH)R
5
R
7
 (whilst if R
3
 is
the same as R
5
, R
5
 can only denote H if at least one
of the substituents R
1
 and R
2
 does not denote H),
R
4
denotes hydrogen, halogen, OH, C
1-4
-alkoxy,
R
5
denotes H, C
1-12
-alkyl, phenyl, phenyl optionally
substituted by halogen, C
1-4
-alkyl, C
1-4
-alkoxy or
C
2-5
-acyl,
R
6
denotes C
1-12
-alkyl, phenyl, or phenyl optionally
substituted by halogen, C
1-4
-alkyl, C
1-4
-alkoxy or
C
2-5
-acyl,
R
7
denotes H or C
1-12
-alkyl, 
R
8
denotes C
2-5
-acyl,
A
denotes one of the groups

X
1
-A
1
-X
2
X
2
-A
2
-X
3
X
4
-A
2
-X
2
(CH
2
)
1-2
-NH-CO-(CH
2
)
1-3
-X
2
-CH=CH-A
2
-X
2
B
denotes CH=CH, CH=N, S or

A
1
denotes C
2-4
-alkylene, cis- or trans-CH
2
-CH=CH-CH
2
,
CH
2
-C≡C-CH
2
 or

A
2
denotes C
1-5
-alkylene,
X
1
denotes O, NH, S, SO, SO
2
, CO or CH
2
,
X
2
denotes O, NH or S,
X
3
denotes NH-CO, CO-NH or SO
2
-NH,
X
4
denotes NH-CO, CO-NH, NH-SO
2
 or SO
2
-NH,

with the proviso that if

B
denotes -CH=CH- and
X
1
denotes oxygen or sulphur and
X
2
denotes oxygen or sulphur and
A
1
denotes C
2-4
-alkylene, cis- or trans-CH
2
-CH=CH-CH
2
,
CH
2
-C≡C-CH
2
 or 


and
one of the groups R
1
, R
2
 or R
3
 denotes -O-C
1-12
-alkyl,

at least one of the other groups R
1
, R
2
 or R
3
 cannot be
hydrogen, halogen, CF
3
, OH, C
1-12
-alkyl or -O-C
1-12
-alkyl,

and with the proviso that if

B
denotes -CH=CH-
R
4
denotes hydrogen,
X
1
 and X
2
denote oxygen,
A
1
denotes C
3
- or C
4
-alkylene

and the amidino group is in the meta position to the
group A,

R
1
, R
2
 or R
3
 cannot denote phenyl, NH
2
, chlorine, methoxy
or CF
3
,

as racemates, in enantiomerically pure or concentrated
form, possibly as pairs of diastereomers and in cis- or

trans-form and as free bases or as salts, preferably
with physiologically acceptable acids.
Compounds according to claim 1 of general formula


wherein

R
1
, R
2
,
which may be identical or different, denote
R
7
, OR
7
, COR
6
, or together denote the double bonded
groups-CR
8
=CH-CH=CH-,-CH=CR
8
-CH=CH-, -O-CH
2
-CH
2
- or
-CO-CH
2
-CH
2
-O-, linked with adjacent carbon atoms of 
the benzene ring, whilst these groups may in turn

be substituted by C
1-4
-alkyl,
R
3
denotes halogen, OH, CF
3
, R
5
, OR
6
, COR
6
, SR
6
, SOR
6
,
SO
2
R
6
, SO
2
NR
5
R
7
, NR
5
R
7
 or C(OH)R
5
R
7
 (whilst if R
3
 is
equal to R
5
, R
5
 can only denote H if at least one of
the substituents R
1
 and R
2
 does not denote H),
R
5
denotes H, C
1-2
-alkyl, phenyl, phenyl optionally
substituted by halogen, C
1-4
-alkyl, C
1-4
-alkoxy or
C
2-5
-acyl,
R
6
denotes C
1-12
-alkyl, phenyl, or phenyl optionally
substituted by halogen, C
1-4
-alkyl, C
1-4
-alkoxy or
C
2-5
-acyl,
R
7
denotes H or C
1-12
-alkyl,
R
8
denotes C
2-5
-acyl,

and

A
denotes the group X
1
-A
1
-X
2
 (II) wherein
A
1
denotes C
2-4
-alkylene, cis- or trans-CH
2
-CH≡CH-CH
2
,
CH
2
-C≡C-CH
2
 or

X
1
denotes O, NH, S, SO, SO
2
, CO or CH
2
,
X
2
denotes O, NH or S,

with the proviso that if

X
1
denotes oxygen or sulphur and 
X
2
denotes oxygen or sulphur and
A
1
denotes C
2-4
-alkylene, cis- or trans-CH
2
-CH=CH-CH
2
,
CH
2
-C≡C-CH
2
 or


and

one of the groups R
1
, R
2
 or R
3
 denotes -O-C
1-12
-alkyl, at
least one of the other groups R
1
, R
2
 or R
3
 cannot denote
hydrogen, halogen, CF
3
, OH, C
1-12
-alkyl or -O-C
1-12
-alkyl,

as racemates, in enantiomerically pure or concentrated
form, optionally as pairs of diastereomers and in cis or

trans form and as free bases or salts, preferably with
physiologically acceptable acids.
Compounds according to claim 1 or 2, wherein
R
1
/R
2
/R
3
 have the meanings C
2-5
-acyl/H/H;

C
6
H
5
CO/H/H; C
1-4
-alkyl/OH/H;

C
2-5
-acyl/C
1-4
-alkyl/H;

C
2-5
-acyl/oH/C
1-4
-alkyl;

OH/C
2-5
-acyl/C
1-4
-alkyl.
Compounds according to claim 1, 2 and 3,
characterised in that A denotes

O-(CH
2
)
2
-O, O-(CH
2
)
4
-O or

Compounds according to-claim 1, 2, 3 or 4,
characterised in that the group



is acetylphenyl.
Compounds according to claim 1, 3, 4 or 5,
characterised in that the group



represents

Pharmaceutical compositions, characterised in that
they contain a compound according to claims 1 to 6.
Use of compounds according to claims 1 to 6 in the
preparation of pharmaceutical compositions for the

treatment of diseases in which inflammatory and/or
allergic processes are involved, especially asthma,

ulcerative colitis, psoriasis and for treating
gastropathy induced by non-steroidal antiphlogistics.
Process for preparing compounds according to claims
1 to 6, characterised in that


a) an imidoester of the formula 


wherein R
1
 to R
4
, A and B are as hereinbefore
defined and R preferably represents a C
1-6
-alkyl
group or benzyl, is reacted with ammonia, or
b1) a phenol or thiophenol of the formula


wherein Z denotes OH or SH and R
1
, R
2
 and R
3
 are as
hereinbefore defined, is reacted with a compound of

formula


or


wherein A
1
, A
2
, B, R
4
, X
2
 and X
3
 are as hereinbefore
defined and L denotes a nucleofugic leaving group,

or 


wherein B, R
4
 and Z are as hereinbefore defined, is
reacted with a compound of formula



or


or


or


wherein A
1
, A
2
, R
1
, R
2
, R
3
 and L are as hereinbefore
defined; or
c) an amidoxime of the formula 


wherein A, B and R
1
 to R
4
 are as hereinbefore
defined, is reduced to form the corresponding

amidine.
</CLAIMS>
</TEXT>
</DOC>
